<br>新型 1-羟基吡嗪-2(1H)-one 铁螯合剂在帕金森病体外细胞模型中的合成、理化表征和神经保护作用评估,Dalton Transactions

当前位置： X-MOL 学术 › Dalton Trans. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

新型 1-羟基吡嗪-2(1H)-one 铁螯合剂在帕金森病体外细胞模型中的合成、理化表征和神经保护作用评估
Dalton Transactions ( IF 3.5 ) Pub Date : 2022-02-11 , DOI: 10.1039/d1dt02604f
Frank W Lewis ₁ , Kathleen Bird ₁ , Jean-Philippe Navarro ₁ , Rawa El Fallah ₂ , Jeremy Brandel ₂ , Véronique Hubscher-Bruder ₂ , Andrew Tsatsanis _{3,

4} , James A Duce _{3,

4} , David Tétard ₁ , Samuel Bourne ₅ , Mahmoud Maina ₅ , Ilse S Pienaar _{5,

6}

Affiliation

铁失调、多巴胺耗竭、细胞氧化应激和 α-突触核蛋白错误折叠是帕金森病进展中的关键神经元病理特征。具有一种或多种治疗作用模式的铁螯合剂长期以来一直被建议作为其治疗的疾病修饰疗法。本研究合成了新型1-羟基吡嗪-2( 1H )-酮铁螯合剂，并评估了其理化性质、铁螯合能力、抗氧化能力以及在帕金森病细胞培养模型中的神经保护作用。物理化学性质（log β 、log D _7.4 、pL _0.5 ）表明这些配体穿透细胞膜并形成较弱铁络合物的能力比密切相关的 1-羟基吡啶-2(1 H )-one 更差。尽管如此，我们表明这些配体在体外针对儿茶酚胺能神经毒素 6-羟基多巴胺提供的神经保护水平与之前使用 1-羟基吡啶-2(1 H )-one 和临床使用的铁螯合剂去铁酮所观察到的神经保护水平相当。与对照相比，其中两种配体将细胞活力恢复至 ≥89%。其中两个配体被赋予了额外的酚部分，试图衍生出具有双重铁螯合/抗氧化活性的多功能螯合剂。然而，这些配体的神经保护水平并不高于缺乏该部分的配体，这表明这些配体的神经保护特性主要是由于细胞内不稳定铁的螯合和钝化，防止自由基和活性氧的产生，否则会导致帕金森病中出现的神经元细胞死亡。

"点击查看英文标题和摘要"

Synthesis, physicochemical characterization and neuroprotective evaluation of novel 1-hydroxypyrazin-2(1H)-one iron chelators in an in vitro cell model of Parkinson's disease

Iron dysregulation, dopamine depletion, cellular oxidative stress and α-synuclein protein mis-folding are key neuronal pathological features seen in the progression of Parkinson's disease. Iron chelators endowed with one or more therapeutic modes of action have long been suggested as disease modifying therapies for its treatment. In this study, novel 1-hydroxypyrazin-2(1H)-one iron chelators were synthesized and their physicochemical properties, iron chelation abilities, antioxidant capacities and neuroprotective effects in a cell culture model of Parkinson's disease were evaluated. Physicochemical properties (log β, log D_7.4, pL_0.5) suggest that these ligands have a poorer ability to penetrate cell membranes and form weaker iron complexes than the closely related 1-hydroxypyridin-2(1H)-ones. Despite this, we show that levels of neuroprotection provided by these ligands against the catecholaminergic neurotoxin 6-hydroxydopamine in vitro were comparable to those seen previously with the 1-hydroxypyridin-2(1H)-ones and the clinically used iron chelator Deferiprone, with two of the ligands restoring cell viability to ≥89% compared to controls. Two of the ligands were endowed with additional phenol moieties in an attempt to derive multifunctional chelators with dual iron chelation/antioxidant activity. However, levels of neuroprotection with these ligands were no greater than ligands lacking this moiety, suggesting the neuroprotective properties of these ligands are due primarily to chelation and passivation of intracellular labile iron, preventing the generation of free radicals and reactive oxygen species that otherwise lead to the neuronal cell death seen in Parkinson's disease.

更新日期：2022-02-11

点击分享查看原文

点击收藏

公开下载

阅读更多本刊新发论文本刊介绍/投稿指南